The Korean Journal of Medicine

  • 제93권4호
  • /
  • Pages.324-335
  • /
  • 2018
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

2018 대한부정맥학회 심방세동 위험인자와 동반된 심혈관계 질환의 발견과 관리

2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation

  • 이소령 (순천향대학교 서울병원 심장내과) ;
  • 이영수 (대구가톨릭대학교병원 순환기내과) ;
  • 임우현 (서울대학교 보라매병원 순환기내과) ;
  • 김태훈 (연세대학교 의과대학 세브란스병원 심장내과) ;
  • 차명진 (서울대학교병원 순환기내과) ;
  • 이지현 (연세대학교 원주의과대학 원주세브란스기독병원 심장내과) ;
  • 백용수 (인하대학교병원 순환기내과) ;
  • 임홍의 (고려대학교 구로병원 순환기내과) ;
  • 정보영 (연세대학교 의과대학 세브란스병원 심장내과) ;
  • 김준수 (성균관대학교 삼성서울병원 순환기내과) ;
  • 이만영 (가톨릭대학교 여의도성모병원 심장내과)
  • Lee, So-Ryoung (Division of Cardiology, Department of Internal Medicine, Soon Chun Hyang University Hospital) ;
  • Lee, Young Soo (Division of Cardiology, Department of Internal Medicine, Daegu Catholic University Medical Center) ;
  • Lim, Woo-Hyung (Division of Cardiology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center) ;
  • Kim, Tae-Hoon (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Cha, Myung-Jin (Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Ji-Hyun (Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Baek, Yong-Soo (Division of Cardiology, Department of Internal Medicine, Inha University Hospital) ;
  • Lim, Hong Euy (Division of Cardiac Electrophysiology, Cardiovascular Center, Korea University Guro Hospital) ;
  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Kim, June Soo (Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Man-Young (Divison of Cardiology, Department of Internal Medicine, The Catholic University of Korea Yeouido St. Mary's Hospital)
  • 발행 : 2018.08.01
⟨ 이전 논문 다음 논문 ⟩

초록

A number of concomitant conditions and cardiovascular diseases are closely related to the development of atrial fibrillation (AF), AF recurrence, and AF-associated complications. Detection, prevention, and treatment of such conditions are essential for the prevention of AF and its disease burden. This article discusses the clinical conditions and concomitant diseases associated with AF including heart failure, hypertension, diabetes, obesity, chronic respiratory diseases, and kidney disease based on the 2016 European Society of Cardiology guidelines for the management of AF and recently updated clinical data, particularly in patients with heart failure. Furthermore, we provide recommendations for the prevention, diagnosis, and management of these conditions.

키워드

참고문헌

  1. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222-2231. https://doi.org/10.1016/j.jacc.2014.09.028
  2. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050-2060. https://doi.org/10.1001/jama.2013.280521
  3. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013;9:123-127. https://doi.org/10.2174/1573403X11309020005
  4. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 2011;13 Suppl 2:ii13-ii17. https://doi.org/10.1093/europace/eur289
  5. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health 2012;15:240-248. https://doi.org/10.1016/j.jval.2011.09.009
  6. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250-3257.
  7. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004. https://doi.org/10.1016/j.jacc.2006.01.060
  8. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660-666. https://doi.org/10.1016/j.ijcard.2015.10.220
  9. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the framingham heart study. Circulation 2003;107:2920-2925. https://doi.org/10.1161/01.CIR.0000072767.89944.6E
  10. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009;11:676-683. https://doi.org/10.1093/eurjhf/hfp085
  11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200. https://doi.org/10.1093/eurheartj/ehw128
  12. Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016;18:12-36. https://doi.org/10.1093/europace/euv191
  13. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. https://doi.org/10.1056/NEJMoa1409077
  14. Kotecha D, Holmes J, Krum H, et al. Efficacy of ${\beta}$ blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. https://doi.org/10.1016/S0140-6736(14)61373-8
  15. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
  16. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894-1903. https://doi.org/10.1016/j.jacc.2013.01.069
  17. Anselmino M, Matta M, D'Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014;7:1011-1018. https://doi.org/10.1161/CIRCEP.114.001938
  18. Ganesan AN, Nandal S, Luker J, et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ 2015;24:270-280. https://doi.org/10.1016/j.hlc.2014.09.012
  19. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-1785. https://doi.org/10.1056/NEJMoa0708234
  20. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014;172:40-46. https://doi.org/10.1016/j.ijcard.2013.12.180
  21. Kusunose K, Yamada H, Nishio S, et al. Clinical utility of single-beat E/e' obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging 2009;2:1147-1156. https://doi.org/10.1016/j.jcmg.2009.05.013
  22. Li C, Zhang J, Zhou C, Huang L, Tang H, Rao L. Will simultaneous measurement of E/e' index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-valvular atrial fibrillation? Eur J Echocardiogr 2010;11:296-301. https://doi.org/10.1093/ejechocard/jep218
  23. Senechal M, O'Connor K, Deblois J, et al. A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in patients with atrial fibrillation. Echocardiography 2008;25:57-63.
  24. Sohn DW, Song JM, Zo JH, et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 1999;12:927-931. https://doi.org/10.1016/S0894-7317(99)70145-8
  25. Wada Y, Murata K, Tanaka T, et al. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J 2012;76:675-681. https://doi.org/10.1253/circj.CJ-11-0703
  26. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015;65:1668-1682. https://doi.org/10.1016/j.jacc.2015.03.043
  27. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-2307. https://doi.org/10.1016/j.jacc.2010.01.043
  28. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. https://doi.org/10.1016/j.jacc.2004.11.070
  29. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43. https://doi.org/10.1097/MJT.0b013e31804beb59
  30. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92. https://doi.org/10.1016/j.ahj.2005.06.036
  31. GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-1617. https://doi.org/10.1056/NEJMoa0805710
  32. Goette A, Schon N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012;5:43-51. https://doi.org/10.1161/CIRCEP.111.965178
  33. ACTIVE I Investigators, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-938. https://doi.org/10.1056/NEJMoa1008816
  34. Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survIval study in heart failure) study. J Am Coll Cardiol 2012;59:1598-1603. https://doi.org/10.1016/j.jacc.2011.11.063
  35. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237. https://doi.org/10.1056/NEJMoa043399
  36. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol 2003;41:1707-1712. https://doi.org/10.1016/S0735-1097(03)00297-3
  37. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 1999;341:857-865. https://doi.org/10.1056/NEJM199909163411201
  38. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677. https://doi.org/10.1056/NEJMoa0708789
  39. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637-1644. https://doi.org/10.1161/CIRCULATIONAHA.115.019406
  40. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-427. https://doi.org/10.1056/NEJMoa1707855
  41. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199-e267. https://doi.org/10.1161/CIR.0000000000000041
  42. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962. https://doi.org/10.1093/eurheartj/ehw210
  43. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the working group 'Hypertension Arrhythmias and Thrombosis' of the European society of hypertension. J Hypertens 2012;30:239-252. https://doi.org/10.1097/HJH.0b013e32834f03bf
  44. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677. https://doi.org/10.1016/S0735-1097(00)00611-2
  45. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-1214. https://doi.org/10.1093/eurheartj/eht507
  46. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719. https://doi.org/10.1016/j.jacc.2004.10.068
  47. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116. https://doi.org/10.1056/NEJMoa1511939
  48. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006
  49. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the cardiovascular health study). Am J Cardiol 1994;74:236-241. https://doi.org/10.1016/0002-9149(94)90363-8
  50. Nabauer M, Gerth A, Limbourg T, et al. The registry of the german competence network on atrial fibrillation: patient characteristics and initial management. Europace 2009;11:423-434.
  51. Vahanian A, Alfieri O, Andreotti F, et al. Joint task force on the management of valvular heart disease of the European society of cardiology (ESC); European association for cardio-thoracic surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-2496. https://doi.org/10.1093/eurheartj/ehs109
  52. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. Eur Heart J 2005;26:2422-2434. https://doi.org/10.1093/eurheartj/ehi505
  53. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2017;70:252-289. https://doi.org/10.1016/j.jacc.2017.03.011
  54. Moretti M, Fabris E, Morosin M, et al. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 2014;114:1722-1728. https://doi.org/10.1016/j.amjcard.2014.09.007
  55. Eguchi K, Ohtaki E, Matsumura T, et al. Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 2005;26:1866-1872. https://doi.org/10.1093/eurheartj/ehi272
  56. Lim E, Barlow CW, Hosseinpour AR, et al. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 2001;104(12 Suppl 1):I59-I63. https://doi.org/10.1161/hc37t1.094813
  57. Maan A, Heist EK, Passeri J, et al. Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol 2015;115:220-226. https://doi.org/10.1016/j.amjcard.2014.10.027
  58. Ngaage DL, Schaff HV, Barnes SA, et al. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery? Ann Thorac Surg 2006;82:1392-1399. https://doi.org/10.1016/j.athoracsur.2006.04.004
  59. Ngaage DL, Schaff HV, Mullany CJ, et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified? Ann Thorac Surg 2007;84:434-442; discussion 442-443. https://doi.org/10.1016/j.athoracsur.2007.04.036
  60. Barbash IM, Minha S, Ben-Dor I, et al. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015;85:468-477. https://doi.org/10.1002/ccd.25708
  61. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988;19:937-941. https://doi.org/10.1161/01.STR.19.8.937
  62. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of valvular heart disease of the European society of cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1-S44. https://doi.org/10.1093/ejcts/ezs455
  63. Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. Europace 2014;16:1720-1725. https://doi.org/10.1093/europace/euu178
  64. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755-759. https://doi.org/10.1016/0003-4975(95)00887-X
  65. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964;1:1209-1212. https://doi.org/10.1136/bmj.1.5392.1209
  66. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 2014;35:3328-3335. https://doi.org/10.1093/eurheartj/ehu352
  67. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-1428. https://doi.org/10.1016/j.jacc.2012.06.030
  68. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-2891. https://doi.org/10.1161/hc4901.101760
  69. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107. https://doi.org/10.1038/nri2925
  70. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-1135. https://doi.org/10.1093/eurheartj/ehp055
  71. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. Pflugers Arch 2010;460:295-306. https://doi.org/10.1007/s00424-009-0771-y
  72. Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015;29:88-92. https://doi.org/10.1016/j.jdiacomp.2014.09.002
  73. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol 2015;26:223-225. https://doi.org/10.1111/jce.12560
  74. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study). Am J Cardiol 2014;114:1217-1222. https://doi.org/10.1016/j.amjcard.2014.07.045
  75. Overvad TF, Skjoth F, Lip GY, et al. Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study. Stroke 2015;46:2168-2174. https://doi.org/10.1161/STROKEAHA.115.009371
  76. Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123. https://doi.org/10.1186/s12933-014-0123-x
  77. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013;167:2412-2420. https://doi.org/10.1016/j.ijcard.2013.01.184
  78. Lip GYH, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. Chest 2015;147:1103-1110. https://doi.org/10.1378/chest.14-2096
  79. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol 2014;7:620-625. https://doi.org/10.1161/CIRCEP.113.001244
  80. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D and McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006;27:96-106. https://doi.org/10.1093/eurheartj/ehi506
  81. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J 2008;155:310-315. https://doi.org/10.1016/j.ahj.2007.10.004
  82. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477. https://doi.org/10.1001/jama.292.20.2471
  83. Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999;83:1242-1247. https://doi.org/10.1016/S0002-9149(99)00066-1
  84. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol 2011;57:1368-1374. https://doi.org/10.1016/j.jacc.2010.10.042
  85. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135. https://doi.org/10.1001/jama.282.22.2131
  86. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013;126:640.e9-e17. https://doi.org/10.1016/j.amjmed.2012.11.024
  87. Baek YS, Yang PS, Kim TH, et al. Delayed recurrence of atrial fibrillation 2years after catheter ablation is associated with metabolic syndrome. Int J Cardiol 2016;223:276-281. https://doi.org/10.1016/j.ijcard.2016.08.222
  88. Baek YS, Yang PS, Kim TH, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc 2017;6:e004705. https://doi.org/10.1161/JAHA.116.004705
  89. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159-2169. https://doi.org/10.1016/j.jacc.2015.03.002
  90. Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 2015;66:985-996. https://doi.org/10.1016/j.jacc.2015.06.488
  91. Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of body mass index on atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing Clin Electrophysiol 2013;36:748-756. https://doi.org/10.1111/pace.12106
  92. Jongnarangsin K, Chugh A, Good E, et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:668-672. https://doi.org/10.1111/j.1540-8167.2008.01118.x
  93. Sivasambu B, Balouch MA, Zghaib T, et al. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients. J Cardiovasc Electrophysiol 2018;29:239-245. https://doi.org/10.1111/jce.13388
  94. Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and quality of life in atrial fibrillation patients after catheter ablation: a meta-analysis and systematic review. Clin Cardiol 2013;36:269-275. https://doi.org/10.1002/clc.22108
  95. Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007;50:234-242. https://doi.org/10.1016/j.jacc.2007.03.040
  96. Shoemaker MB, Muhammad R, Farrell M, et al, Saavedra P, Ellis C, Whalen SP and Darbar D. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368-373. https://doi.org/10.1016/j.amjcard.2012.10.013
  97. Cha YM, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation 2008;117:2583-2590. https://doi.org/10.1161/CIRCULATIONAHA.107.716712
  98. Hoyt H, Bhonsale A, Chilukuri K, et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011;8:1869-1874. https://doi.org/10.1016/j.hrthm.2011.07.025
  99. Letsas KP, Siklody CH, Korantzopoulos P, et al. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. Int J Cardiol 2013;164:94-98. https://doi.org/10.1016/j.ijcard.2011.06.092
  100. Vizzardi E, Sciatti E, Bonadei I, D'Aloia A, Curnis A, Metra M. Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc Med (Hagerstown) 2017;18:490-500. https://doi.org/10.2459/JCM.0000000000000043
  101. Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update. Curr Cardiol Rev 2012;8:265-272. https://doi.org/10.2174/157340312803760811
  102. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325. https://doi.org/10.1152/physrev.00031.2009
  103. Lin YK, Lai MS, Chen YC, et al. Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 2012;122:121-132. https://doi.org/10.1042/CS20110178
  104. Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a different sort. Am J Cardiol 2012;110:1071. https://doi.org/10.1016/j.amjcard.2012.07.001
  105. Patel D, Mohanty P, Di Biase L, et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010;3:445-451. https://doi.org/10.1161/CIRCEP.109.858381
  106. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013;62:300-305. https://doi.org/10.1016/j.jacc.2013.03.052
  107. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013;10:331-337. https://doi.org/10.1016/j.hrthm.2012.11.015
  108. Neilan TG, Farhad H, Dodson JA, et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc 2013;2:e000421. https://doi.org/10.1161/JAHA.113.000421
  109. Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014;16:1309-1314. https://doi.org/10.1093/europace/euu066
  110. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095-1105. https://doi.org/10.1056/NEJMoa1506459
  111. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29(7 Suppl):S71-S78. https://doi.org/10.1016/j.cjca.2013.04.005
  112. Roldan V, Marin F, Fernandez H, et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111:1159-1164. https://doi.org/10.1016/j.amjcard.2012.12.045
  113. Lubitz SA, Lunetta KL, Lin H, et al. Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol 2014;63:1200-1210. https://doi.org/10.1016/j.jacc.2013.12.015
  114. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154-162. https://doi.org/10.1016/S0140-6736(14)61774-8
  115. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-2461. https://doi.org/10.1161/01.CIR.96.7.2455
  116. Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012;345:e7895. https://doi.org/10.1136/bmj.e7895
  117. Kim EJ, Lyass A, Wang N, et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J 2014;167:123-126. https://doi.org/10.1016/j.ahj.2013.10.012
  118. Vermond RA, Geelhoed B, Verweij N, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 2015;66:1000-1007. https://doi.org/10.1016/j.jacc.2015.06.1314
  119. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-571. https://doi.org/10.1016/j.jacc.2006.08.060
  120. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32. https://doi.org/10.1161/CIRCEP.110.957100
  121. Chamberlain AM, Agarwal SK, Folsom AR, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 2011;8:1160-1166. https://doi.org/10.1016/j.hrthm.2011.03.038
  122. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014;64:281-289. https://doi.org/10.1016/j.jacc.2014.03.048
  123. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572-1577. https://doi.org/10.1016/j.amjcard.2009.01.374

피인용 문헌

  1. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265